Objective. Ovarian cancer cells often exist in vivo as multicellular spheroids. Spheroid 39 formation in vitro has been used to enrich for cancer stem cell populations from primary 40 tumors. Such spheroids exhibit drug resistance and slow proliferation, suggesting 41 involvement in disease recurrence. Our objectives were to characterize cancer spheroid 42 phenotypes, determine gene expression profiles associated with spheroid forming 43 capacity and to evaluate the responsiveness of spheroids to commonly used and novel 44 therapeutic agents. 45
were grown on non-adherent tissue culture plates in serum-free media. Cell proliferation 48 was measured using MTT assays and Ki67 immunostaining. Affymetrix HT U133A gene 49 expression data was used to identify differentially expressed genes based on spheroid 50 forming capacity. Matched monolayers and spheroids (N=7 pairs) were tested for 51 response to cisplatin, paclitaxel and 7-hydroxystaurosporine (UCN-01) while 52 mitochondrial inhibition was performed using oligomycin. Xenograft tumors from 53
INTRODUCTION 71
Ovarian cancer is the fifth leading cause of cancer death among women in the 72
United States with the highest mortality rate of all gynecologic cancers 1 . Although 70% of 73 ovarian cancer patients achieve complete clinical remission following cytoreductive 74 surgery and treatment with a platinum/taxane-based chemotherapeutic regimen, the 75 majority suffer relapse with disease that has acquired or will develop chemoresistance 2-5 . 76
New therapies aimed at reducing disease recurrence are urgently needed in order to 77 improve survival. 78 79 Cancer stem-like cells (CSLCs) that are able to enter into a state of dormancy 80 and later regenerate tumors may provide a causal explanation for ovarian cancer relapse 81 after initially successful treatments 4, 6 . Furthermore, cells with CSLC characteristics are 82 naturally resistant to chemotherapeutic agents, in part due to expression of drug 83 transporters and a slow rate of proliferation 7 . In patients with advanced ovarian cancer, 84 ascites fluid often accumulates in the peritoneal cavity and can become enriched with 85 tumor cells that aggregate together to form multilayered spheroids 8 . These spheroids 86 contain CSLCs 9 and exhibit resistance to chemotherapy 4, 10 . They are also capable of 87 embedding into other tissues and this feature may be responsible for the "grains of sand" 88 texture in the peritoneal cavity in women with advanced stage serous ovarian cancer at 89 the time of initial cytoreductive surgery 11 . The embedded cells may enter into a state of 90 dormancy, thus rendering them resistant to commonly use chemotherapeutics that target 91 actively proliferating cells. These dormant cells may later awaken to initiate growth and 92 recurrent disease once conditions are favorable. Thus, targeting these spheroids may 93 offer a plausible approach to achieve long-term remission of women with advanced 94 ovarian cancer. To this end, we grew ovarian cancer cells on non-adherent plates using 95 serum-free spheroid culture conditions, which results in aggregation of cells with 96 spheroid-forming capacity into spheroids [12] [13] [14] . We then sought to identify novel candidate 97 drugs that are effective at targeting these spheroids. 98
99
In the present study, spheroid-forming ovarian cancer cells indeed exhibited 100 characteristics of cellular dormancy, a condition of greatly reduced growth and/or 101 quiescence that is associated with drug resistance and disease recurrence 4, 15 . We 102 previously reported that the protein kinase C inhibitor, UCN-01 (7-hydroxystaurosporine), 103 had higher efficacy against slow proliferating and/or quiescent ovarian cancer cells 16 . 104
Here, we assessed the efficacy of UCN-01 against ovarian cancer spheroids and 105 compared these results to the efficacy of cisplatin and paclitaxel. In addition, analysis of 106 gene expression profiles in spheroid-forming ovarian cancer cell lines versus cell lines 107 that do not form spheroids suggested that the activity of mitochondrial pathway genes 108 contributes to spheroid forming capacity. Mitochondria are known to play a central role in 109 regulating cellular metabolism and produce adenosine triphosphate (ATP) through the 110 citric acid cycle 17 . Oligomycin, an inhibitor of mitochondrial ATP synthase 18 , repressed 111 spheroid-formation in a dose-dependent manner. In a mouse xenograft model we found 112 that UCN-01 or mitochondrial inhibitor Oltipraz prolonged the disease-free interval 113 following carboplatin treatment. This markedly contrasted with results from continued 114 carboplatin treatment, in which the mice showed a rapid increase in tumor volume. 115
Collectively, these results show that cells cultured under serum-free spheroid culture 116 conditions are induced into cellular dormancy, and further suggest that the mitochondrial 117 pathway is a promising target for eradication of these dormant ovarian cancer cells. 118
RESULTS 120
Twenty two cancer cell lines were used to perform anchorage-independent growth 121 assays, the first bioassay developed for CSLCs 19 . Average numbers of colonies formed 122 per microscopic field that were >100 µm in diameter for these cell lines ranged from 0 to 123 7.15 ( Table 1) . The cell lines CAOV3, DOV13, and OVCA429 did not form any colonies. 124 OVCA420 only formed colonies <100 µm in diameter and TYK-nu, SKOV8, 41M, 125 OVCA432, OVCAR3, and FUOV1 formed a small number of colonies (>0 but ≤ 0.1 126 colonies/microscopic field). Nine cell lines with ≥ 2.9 colonies/microscopic field were 127 categorized as having high tumorigenic potential, including PEO1, OVCAR8, 128 OVARY1847, OV90, HEYA8, OVCAR2, CAOV2, HEY, and HEYC2. 129 and the ability of the spheroids to undergo serial passaging are shown in Table S1 . Five 135 cell lines were able to undergo passage more than five times and were determined to 136 have increased capacity to form spheroids under serum-free spheroid culture conditions. 137
On the other hand, OVARY1847, OV90, PEO1 and OVCAR8 formed either no or few 138 spheroids, and most were not able to survive beyond two passages (data not shown). 139
Representative monolayer cells and spheroids of HEYA8 are presented in Figure 1A . 140
Primary ovarian cancers were also used for non-adherent spheroid assays. A number of 141 spheroids were obtained initially from seven of eight tumors, but only few spheroids, if 142 any, were formed following five passages. Representative spheroids for primary ovarian 143 cancers are also shown in Figure 1A . 144 145 Sustainable spheroid formation beyond ten passages was not achieved for the 146 ovarian cancer cell lines tested nor for spheroids derived from primary ovarian cancers. 147
However, a small number of single cells remained viable in serum-free spheroid culture 148 even three months after initiation of the culture. Surviving primary ovarian cancer cells in 149 serum-free spheroid culture conditions for 83, 90, and 98 days were tentatively 150 transferred into tissue culture-treated dishes. They subsequently adhered to the dishes 151 and resumed growth. Representative staining with a pan-cytokeratin marker is shown in 152 Figure 1B . In order to investigate the ability of the cells within the spheroids to self-renew, 153 a characteristic of stem cells, single cell cloning was performed by serial dilution of 154 spheroid-forming cells under serum-free spheroid culture conditions. No secondary 155 spheroids were formed within the three-month duration of the experiment (data not 156 shown). 157
158
Serial cell proliferation assays demonstrated that HEYA8 ovarian cancer 159 monolayer cells exhibit rapid growth and became confluent three days after plating, while 160 the growth of HEYA8 cells in serum-free spheroid culture was strongly repressed 161
(unpaired t-test, P<0.0001 on days 2 and 3; Figure 1C ). The proportion of proliferation 162 marker Ki-67 positive cells was decreased in the spheroid-forming cells of HEYA8 (7 th day 163 in serum-free spheroid culture), as compared to HEYA8 grown as monolayer cells (8% 164 versus 87%; Figure 1D ). Spheroids from a primary tumor (28 th day; just before 4 th 165 passage) also exhibited a relatively small population of Ki-67 positive cells ( Figure 1D) . Gene expression profiling was performed to identify genes and/or pathways that 179 distinguish spheroid-forming cells (N=5) from the cell lines that do not have 180 spheroid-forming capacity (N=4). Of 22,277 probes on the Affymetrix U133 HTA gene 181 expression microarray platform, 1,358 probes (1,066 named genes) were significantly 182 increased in cell lines that have high spheroid forming capacity under serum-free 183 spheroid culture conditions (Table S2) , while 1,441 probes, representing 1,114 named 184 genes, were significantly increased in cell lines with low potential to form spheroids 185 (Table S3 ). A heat map of all 2,799 probes with significant differences in expression 186 between the spheroid forming and non-spheroid forming groups is shown in Figure 3 . 187
Functional annotation clustering analysis of the 1,066 genes whose expression is 188 increased in spheroid forming cells showed the most significant enrichment for genes 189 involved in mitochondrial function (137 genes, 11.6-fold enrichment; FDR=2.3e -19 ) and 190 DNA damage/repair (46 genes, 5.9-fold enrichment; FDR=1.2e -5 ) ( Table 2 ; full list in 191 Table S4 ). For the 1,114 genes that are more highly expressed in the cells with low 192 spheroid-forming capacity, metal binding (5.6-fold enrichment; 268 genes, p=1.8e -10 , 193 FDR=2.6e -7 ) and cell junctions (4.2-fold enrichment; 67 genes, p=4.3e -7 , FDR=6.1e -4 ) 194
were the most significant annotations ( HEYA8 cells grown as monolayers and spheroids at 5 µg/ml but reduced cell survival 201 81.4% and 70.4%, respectively, at 25 µg/ml (p < 0.0001 for both; Figure 4A ), Cell-cell 202 contact within spheroids was diminished at 5 µg/ml and spheroids were nearly completely 203 dissociated at 25 µg/ml Oligomycin (Figure 4B) . 204
205
Patients with platinum resistant/refractory ovarian cancer have poor clinical prognosis 20 . 206
Platinum-resistant ovarian cancer tends to relapse within the first six months after the end 207 of first-line chemotherapy (carboplatin and/or paclitaxel) 21 . We have shown that UCN-01 208 and Oltipraz function preferentially on slowly proliferating cells in vitro. Previous studies 209 have shown that slow-cycling subpopulations of quiescent cancer cells include cancer 210 stem-like cells and contribute to chemoresistance and recurrence 22 . In order to test our 211 hypothesis that UCN-01 and Oltipraz would be effective in treating platinum 212 resistant/refractory ovarian cancer, we employed a novel mouse model of carboplatin 213 resistance. 214 model. We first generated stable cell lines that express luciferase (LUC) and green 217 fluorescent protein (GFP) in CAOV2 ovarian cancer cells. The LUC/GFP positive cells 218 (CAOV2-GFP/LUC) were enriched by flow cytometry for GFP positive signals. Forty mice 219 were injected intraperitoneally with 3.5X10 5 CAOV2-GFP/LUC cells. After seven days, 26 220 mice had visible tumors by in vivo live imaging with a mean of 3.2X10 7 total photon flux. 221
Six of these mice received no treatment (Arm 5). The remaining 20 of these 222 tumor-bearing mice were treated once every four days with carboplatin at 80 mg/kg for a 223 total of three rounds of treatment, until tumor signal was reduced to an average of 50% 224 total photon flux (total photon flux from 3.2X10 7 to 1.5X10 7 ). The mice were then assigned 225 to arms for the secondary treatment as indicated in Figure 5A . The secondary treatment 226 regimen is described in detail in Materials and Methods. The dosing regimen for each 227 mouse is shown in Table 3 and the average total photon flux from each experimental arm 228 is summarized in Table S6 . The mice receiving carboplatin followed by additional 229 carboplatin (Arm 1) or no additional treatment (Arm 4) showed decreased tumor size from 230 the primary carboplatin treatment, but tumor growth resumed after treatment was 231 terminated ( Figure 5A ). We found that mice experienced a reduction in tumor burden 232 after three rounds of treatments with carboplatin, but this improvement was reversed with 233 further carboplatin treatment due to apparent acquired resistance. Mice in the 234 experimental arms that received carboplatin primary treatment followed by UCN-01 (Arm 235 2) or Oltipraz (Arm 3) showed little to no evidence of tumor re-growth ( Figure 5A and 5B) . 236
As expected, mice that received no treatment showed progressive tumor growth 237 throughout the study and reached humane endpoints sooner than all other mice. 238
Continued carboplatin treatment in Arm 4 showed some benefit relative to no treatment or 239 no continued treatment ( . In breast cancer, a majority of disseminated tumor cells persist in a dormant state 277 in the bone marrow and are distinguished by having a CD44 + / CD24 -/low cell surface 278 marker profile 34 . We sought to enrich for ovarian CSLCs using the serum-free culture 279 model reported previously 14 , but failed to reproduce sustainable spheroids with 280 self-renewal capability. This shortcoming may be because the cancer cells investigated 281 did not contain CSLCs as previously discussed 12 . CD44 is present on CSLCs of a 282 number of cancer types, including breast, prostate, colon, and ovarian cancer 14, 36-39 as 283 well as in cell lines 12, 40 . In our study, CD44 expression was strongly and positively 284 correlated with the capacity for anchorage-independent colony formation and the ability of 285 spheroids to undergo passaging, although CD44 expression was not correlated with 286 spheroid numbers. CD24, a cell surface marker that is absent on breast CSLCs, here 287 discriminated the capacity for spheroid formation among the cancer cell lines. These data 288 also suggests a relationship between CSCL marker expression and the ability to enter 289 into a dormant state. It is well known that spheroid formation is determined by both 290 intrinsic properties of cells and by the cellular microenvironment 41 . Accordingly, we found 291 that OVARY1847, OV90, PEO1, and OVCAR8 spheroid cells did not survive over a 292 prolonged period in serum-free spheroid culture, while they could be expanded in regular 293 media (Table S1). These findings suggest that the microenvironment indeed plays an 294 important role in the selection of a specific population of cancer cells that enter into 295 cellular dormancy. 296 297 Drug resistance remains a major problem in the treatment of recurrent ovarian cancer. 298
Spheroid models have been used primarily as an in vitro model for three-dimensional 299 solid tumors to investigate mechanisms of drug resistance 42 . Spheroid cells are known to 300 become refractory to conventional chemotherapeutic agents, especially to paclitaxel 301 when compared to monolayer cells 43, 44 . Therefore, eradication of spheroids within 302 ascites may be quite clinically relevant to decrease the high rate of ovarian cancer 303 recurrence. We previously reported that UCN-01 had higher efficacy against 304 slow-proliferating and/or quiescent cancer cells 16 , and that UCN-01 exhibits higher 305 efficacy against ovarian cancer cells grown as spheroids. This finding is in stark contrast 306 to the increased resistance exhibited by the spheroids to carboplatin and paclitaxel. 307 308 UCN-01 has been evaluated in clinical trials for various malignancies, including ovarian 309 cancer 45-49 . In the ovarian cancer trail, UCN-01 was delivered with topotecan in the 310 recurrent setting, when tumor growth was already evident. In order to delay or prevent 311 recurrent disease, it is likely important to deliver drugs like UCN-01 or Oltipraz when the 312 cells are in a slow-proliferating or dormant state, before the cells begin recurrent growth. 313
This approach has not yet been formally tested in clinical trials with an aim of targeting the 314 residual dormant cancer cell population. Targeting this residual cell population may be a 315 relevant strategy for improving survival of women with high grade invasive ovarian 316 cancer. 317 318 Bioinformatic analyses of the genes showing differential expression between the 319 spheroid-forming and non-spheroid forming ovarian cancer cell lines showed that genes 320 involved in mitochondria functions were elevated and important to the survival of the 321 spheroids in serum-free spheroid culture conditions. UCN-01 is an inhibitor of protein 322 kinase C and cyclin-dependent kinases, and is also known to induce mitochondrial 323 damage and apoptosis 50, 51 . In support of the microarray data analysis, another 324 mitochondrial inhibitor, Oligomycin, reduced cell survival in both monolayer cells and 325 spheroids and also inhibited the ability of the cells in serum-free spheroid culture 326 conditions to maintain their cell-cell contacts and spheroid phenotype. These findings are 327 compatible with another report demonstrating that metabolism-related genes are 328 up-regulated in compact spheroids rather than loose cellular aggregates 52 . Such Our results from the xenograft mouse studies suggest that UCN01 and Oltipraz, and 335 similar drugs that target slower proliferating cells, may have efficacy against residual 336 ovarian cancer cells when delivered after completion of the primary chemotherapeutic 337 regimen and prior to emergence of recurrent disease. Continued carboplatin treatment 338 resulted in tumor regrowth, contrasting with the results from treating with UCN-01 and 339
Oltipraz, in which tumor cells remaining following completion of the carboplatin regimen 340 were apparently not able to initiate growth in the mice, at least during the duration of the 341 experiment. It is likely important that treatment to target the residual cancer cells 342 commenced soon after the completion of the primary chemotherapy. This may be a 343 critically important but underappreciated point since the numbers of residual cancer cells 344 are at a nadir, and presumably more easily targeted. The prior Phase I and II clinical trials 345 in which UCN-01 was tested for efficacy against recurrent ovarian cancer initiated 346 treatment after the recurrent disease was evident 54, 55 . The conclusion was that although 347 well tolerated, UCN-01 (and topotecan, given together in those studies) did not show 348 anti-tumor activity. However, after the disease recurs, the cancer cells are again rapidly 349 dividing, and according to our results here and those we have previously published 16 , 350 these actively proliferating cells would have shown resistance to UCN-01. This may 351 explain the failure to achieve a response in those initial trials. 352
In conclusion, our results support that serum-free spheroid culture can be used 353 that survive initial chemotherapy are likely to be the source of recurrent disease, and we 362 contend that these cells need to be targeted prior to the onset of recurrent disease. Our 363 findings suggest that targeting aspects of mitochondrial function may be a reasonable 364 strategy for decreasing the high recurrence rate of advanced stage ovarian cancers. 365
Cells. Twenty-five ovarian cancer cell lines were grown in RPMI-1640 medium with 369 L-glutamine (Sigma-Aldrich; St. Louis, MO) supplemented with 10% fetal bovine serum in 370 a humidified incubator with 5% CO 2 at 37°C. Cell lines were genetically authenticated 371 with each expansion at the Duke University DNA Analysis Facility to confirm identity of 372 newly-prepared freezer stocks. 373 374 Anchorage-independent growth. Assays for colony formation in soft agar were 375 performed as described 56 . Briefly, 2X RPMI media was prepared from powder and 376 supplemented with fetal bovine serum and antibiotics (Invitrogen; Carlsbad, CA). A 1% 377 agarose solution was made with the RPMI media using low-melting-temperature agarose 378 (Invitrogen). One ml of 0.5% agarose was placed into each well of six-well tissue culture 379 dishes and overlaid with 1 ml of 0.33% agarose prepared in 1x RPMI and containing 2 x 380 10 4 cells. After three weeks incubation at 37°C in a humidified chamber with 5% CO 2 , 381 colonies larger than 100 µm in diameter were counted. The colony number formed for 382 each cell line was determined by averaging the number of colonies >100 µm that were 383 counted in 10-20 microscopic fields at 100X magnification. Data were analyzed using 384
Graphpad Prism software with a p value less than 0.05 considered significant. 385 386 Spheroids. Single dissociated ovarian cancer cells derived from cell lines were plated at 387 500 cells/ml in 2 ml serum-free DMEM-F12 (GIBCO; Invitrogen) supplemented with 5 388 µg/ml insulin (SAFC Biosciences; Lenexa, KS), 20 ng/ml human recombinant EGF 389 (Invitrogen), 10 ng/ml bFGF (R&D Systems; Minneapolis, MN), and 0.4% BSA using 390 6-well ultra-low attachment plates (Corning Life Sciences; Lowell, MA). After 7-10 days in 391 culture, spheroids larger than 50 µm in diameter were counted. To assess the ability of 392 spheroids to undergo serial passaging, dissociated ovarian cancer cells from spheroids 393 were plated at 5X10 3 cells/ml. Cells grown in serum-free spheroid culture were 394 enzymatically dissociated by incubation in a trypsin-EDTA solution (0.025%) for ten 395 minutes and underwent passaging every 7-10 days. Fresh medium (500 µl per well) was 396 added twice a week. Cell viability was measured at each passage using trypan blue 397 staining. The experiments were performed at least in triplicate. 398
Malignant human ovarian tissues. Tumors were obtained from eight patients 399 diagnosed with advanced ovarian cancer at the time of initial cytoreductive surgery at 400
Duke University Medical Center, after receiving approval from the Duke University 401
Institutional Review Board and following provision of written informed consent. Fresh 402 tumors were minced and suspended in serum-free media with growth factors as 403 described above. To further dissociate the tumors, 300 units per ml of both collagenase 404 (Sigma-Aldrich) and hyaluronidase (EMD Biosciences; Gibbstown, NJ) were added 405 followed by overnight incubation in a humidified chamber with 5% CO 2 . The cell 406 suspension was filtered using a 40 µm cell strainer and red blood cells were removed 407 using Histopaque 1077 (Sigma-Aldrich). The cells were resuspended in the media 408 described above and plated on ultra-low attachment plates. To determine the ability of the 409 cells within spheroids to undergo self-renewal, spheroids generated by eight ovarian 410 cancer cell lines and seven primary tumors were dissociated following three to five 411 passages. Cells were plated at single cell dilution into 96-well ultra-low attachment plates 412 under serum-free spheroid culture conditions described above. Microscopic visualization 413
confirmed the presence of one cell per well in the 96-well plates. To investigate whether quiescent cancer cells in serum-free spheroid culture can resume 431 growth in regular media, cells from cell lines and three primary tumors that underwent 432 serial passage in serum-free spheroid culture were collected and plated on tissue-culture 433 treated plates with regular media. Immunostaining with a pan-cytokeratin cocktail 434 antibody, AE1/AE3 (Dako), was used to confirm the epithelial nature of the cancer cells. 435
The Mouse Super Sensitive TM Negative Control, clone HK408-5R (BioGenex; San 436 Ramon, CA) was used as a negative control. 437 438 Drug sensitivity assays. UCN-01 was kindly provided by the National Cancer Institute. 439
Cisplatin, paclitaxel and oligomycin were purchased from Sigma-Aldrich. Cells in regular 440 media were seeded at 3X10 3 cells per well into tissue culture-treated plates, and cells in 441 serum-free sphere culture were plated at 6X10 3 cells per well in 96-well ultra-low 442 attachment plates. Drugs were added 24 hours later, and the cells were incubated in the 443 presence of the drugs for an additional 24 hours (Oligomycin) or 48 hours (all other 444 drugs). Six wells were used for each drug concentration. The cell survival ratio was 445 determined by quantifying the reduction in growth compared with mock-treated cells at 48 446 hours using a standard MTT colorimetric assay (Promega AQueous One). The assay was 447 repeated four times. 448 449 Microarray data. We analyzed our previously generated Affymetrix HG-U133A DNA 450 microarray data for ovarian cancer cell lines (Gene Expression Omnibus: GSE25429). 451
Data analysis was performed using Partek Genomics Suite software (St.Louis, MO). 452
Affymetrix CEL files were normalized using the Robust Multichip Average method 57 . To 453 investigate gene expression profiles that allow cancer cells to survive serum-free 454 spheroid culture conditions, we identified differentially expressed genes between cell 455 lines that have low (n=4) versus high (n=5) capacity to survive under these conditions. We 456 used student t tests with an unadjusted p value cutoff of 0.05, which resulted in the 457 identification of 2,799 probes. Supervised clustering was performed as previously 458 described 58 . Bioinformatics analyses of the genes differentially expressed between cell 459 lines with low and high potential to survive serum-free spheroid culture conditions was 460 done using DAVID 6.8 59, 60 . Following establishment of a measurable tumor, treatment with carboplatin was 485 performed every four days for three weeks at 80 mg/kg of mouse body weight. Tumor 486 signal was monitored by IVIS imaging. Twenty-six mice were responsive to the 487 carboplatin treatment and were randomly grouped for secondary treatment (Table 3) . Table S1 . Spheroid-forming characteristics of ovarian cancer cell lines. Shown are the 735 average numbers of spheroids formed (>50 µM in diameter) after 7-10 days in culture 736 from initial plating of 500 dissociated cells/ml under spheroid culture conditions, and the 737 ability of the spheroids to undergo serial passage under spheroid culture conditions. 738 739  Table S2 . Differentially expressed genes that exhibit increased expression in the high 740 spheroid-forming capacity cell lines that discriminate between high and low potential to 741 survive serum-free spheroid culture. 742 743   Table S3 . Differentially expressed genes that exhibit increased expression in the low 744 spheroid-forming capacity cell lines that discriminate between high and low potential to 745 survive serum-free spheroid culture. 746 747 
